Evidence map›Paper›PMID 38124744›Full record

ArticleFrontiers in immunology2023

Immunogenicity of PE18, PE31, and PPE26 proteins from

María García-Bengoa, Emil Joseph Vergara, Andy C Tran, Lorenzo Bossi, Andrea M Cooper, John E Pearl, Tufária Mussá, Maren von Köckritz-Blickwede, Mahavir Singh, Rajko Reljic

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. The PE/PPE family proteins ofFrontiers in immunology · 2025
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

María García-Bengoa *Institute of Biochemistry, University of Veterinary Medicine Hannover, Hannover, Germany.
Emil Joseph Vergara *Institute for Infection and Immunity, St. George's University of London, London, United Kingdom.
Andy C Tran *Institute for Infection and Immunity, St. George's University of London, London, United Kingdom.
Lorenzo BossiImmunxperts SA, a Q² Solutions Company, Gosselies, Belgium.
Andrea M CooperDepartment of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom.
John E PearlDepartment of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom.
Tufária MussáDepartment of Microbiology, Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique.
Maren von Köckritz-BlickwedeInstitute of Biochemistry, University of Veterinary Medicine Hannover, Hannover, Germany.
Mahavir SinghLIONEX Diagnostics and Therapeutics GmbH, Braunschweig, Germany.
Rajko ReljicInstitute for Infection and Immunity, St. George's University of London, London, United Kingdom.
St George's, University of London · GBUniversity of Leicester · GBUniversity of Veterinary Medicine Hannover, Foundation · DEEduardo Mondlane University · MZLionex (Germany) · DE

Funding

Medical Research Council MR/P011136/1
6 · The paper itself

Abstract

Introduction: The large family of PE and PPE proteins accounts for as much as 10% of the genome of Methods: The investigation involved analyzing the immunoreactivity of the selected proteins using sera from TB patients, IGRA-positive household contacts, and IGRA-negative BCG vaccinated healthy donors from the TB endemic country Mozambique. Antigen-recall responses were examined in PBMC from these groups, including the evaluation of cellular responses in healthy unexposed individuals. Moreover, systemic priming and intranasal boosting with each protein, combined with the Quil-A adjuvant, were conducted in mice. Results: We found that all three proteins are immunoreactive with sera from TB patients, IGRA-positive household contacts, and IGRA-negative BCG vaccinated healthy controls. Likewise, antigen-recall responses were induced in PBMC from all groups, and the proteins stimulated proliferation of peripheral blood mononuclear cells from healthy unexposed individuals. In mice, all three antigens induced IgG antibody responses in sera and predominantly IgG, rather than IgA, responses in bronchoalveolar lavage. Additionally, CD4+ and CD8+ effector memory T cell responses were observed in the spleen, with PE18 demonstrating the ability to induce tissue-resident memory T cells in the lungs. Discussion: Having demonstrated immunogenicity in both humans and mice, the protective capacity of these antigens was evaluated by challenging immunized mice with low-dose aerosol of

Indexed as

Mycobacterium tuberculosisAnimalsAntigens, BacterialBCG VaccineHumansImmunoglobulin GLeukocytes, MononuclearMiceAntigens, BacterialBCG VaccineImmunoglobulin GantigensimmunityPE18PE31PPE26tuberculosisvaccine

Identifiers

PMID38124744
PMCPMC10730732
OpenAlexW4389393404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.